Serum visfatin and vaspin levels in hepatocellular carcinoma (HCC)


Autoři: Monika Pazgan-Simon aff001;  Michał Kukla aff001;  Jolanta Zuwała-Jagiełło aff003;  Aleksandra Derra aff004;  Martyna Bator aff004;  Tomasz Menżyk aff004;  Andrzej Lekstan aff005;  Ewa Grzebyk aff003;  Krzysztof Simon aff001
Působiště autorů: Department of Infectious Diseases and Hepatology, Wrocław Medical University, Wroclaw, Poland aff001;  Department of Gastroenterology and Hepatology, Medical University of Silesia in Katowice, Katowice, Poland aff002;  Department of Pharmaceutical Biochemistry, Wroclaw Medical University, Wroclaw, Poland aff003;  Medical University of Silesia in Katowice, Katowice, Poland aff004;  Department of Digestive Tract Surgery, Medical University of Silesia in Katowice, Katowice, Poland aff005
Vyšlo v časopise: PLoS ONE 15(1)
Kategorie: Research Article
doi: 10.1371/journal.pone.0227459

Souhrn

Hepatocellular carcinoma (HCC) is the most common liver cancer, accountable for 90% cases. Visfatin and vaspin are adipocytokines with various suggested functions and proven significant correlations between BMI and percentage of body fat. The aim was to assess visfatin and vaspin serum levels in HCC patients and controls, compare their levels in patients with different cancer etiology and grade assessed according to the Barcelona-Clinic Liver Cancer (BCLC) staging system. The additional aim was to analyze relationship between analyzed adipokines and metabolic abnormalities and liver disfunction severity. The study was performed on 69 cirrhotic patients (54 males/15 females) with HCC, aged 59.0 ± 12.1 years, and with BMI 29.0 ± 4.5 kg/m2 compared to 20 healthy volunteers. Serum visfatin and vaspin concentrations were significantly increased in HCC patients compared to controls (p = 0.01 and p = 0.02, respectively). Serum vaspin was significantly higher in HCC patients with viral compared to those with non-viral etiology (p = 0.02), with more evident increase in chronic hepatitis C patients (CHC). Serum visfatin levels were significantly higher in patients with higher insulin resistance (p = 0.04) and with platelets count > 100 000/mm3 (p<0.001). Patients with BMI >30 kg/m2 had markedly up-regulated vaspin levels (p = 0.04). There was no difference in vaspin and visfatin serum levels with respect to liver dysfunction and BCLC classification. In conclusion, our study revealed serum vaspin and visfatin to be significantly increased in HCC patients independently of cancer etiology compared to controls. Additionally, serum vaspin was elevated in viral disease, especially in CHC. Vaspin up-regulation can be a compensatory mechanism against IR in HCC patients. Serum visfatin and vaspin, although up-regulated, seem not to be associated with cancer grade and cirrhosis severity.

Klíčová slova:

Adipokines – Adipose tissue – Body mass index – Etiology – Hepatocellular carcinoma – Insulin – Obesity – Platelets


Zdroje

1. Altekruse SF, Devesa SS, Dickie LA, McGlynn KA, Kleiner DE. Histological classification of liver and intrahepatic bile duct cancers in SEER registries. J. Regist. Manag. 2011, 38: 201–205.

2. Gomaa AI, Khan SA, Toledano MB, Waked I, Taylor-Robinson SD. Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World. J. Gastroenterol. 2008, 14: 4300–4308. doi: 10.3748/wjg.14.4300 18666317

3. Said A, Ghufran A. Epidemic of non-alcoholic fatty liver disease and hepatocellular carcinoma. World J. Clin. Oncol. 2017, 8: 429–436. doi: 10.5306/wjco.v8.i6.429 29291167

4. Derra A, Bator M, Menżyk T, Kukla M. Underrated enemy–from nonalcoholic fatty liver disease to cancers of the gastrointestinal tract. Clin. Exp. Hepatol. 2018, 4: 55–71. doi: 10.5114/ceh.2018.75955 29904722

5. Cholankeril G, Patel R, Khurana S, Satapathy SK. Hepatocellular carcinoma in non-alcoholic steatohepatitis: Current knowledge and implications for management. World J Hepatol. 2017, 9: 533–543. doi: 10.4254/wjh.v9.i11.533 28469809

6. Kukla M. Angiogenesis: a phenomenon which aggravates chronic liver disease progression. Hepatol Int. 2013, 7: 4. doi: 10.1007/s12072-012-9391-2 26201617

7. Kukla M, Zwirska-Korczala K, Gabriel A. Chemerin, vaspin and insulin resistance in chronic hepatitis C. J. Viral. Hepat. 2010, 17: 661–7. doi: 10.1111/j.1365-2893.2009.01224.x 20002564

8. Kukla M, Mazur W, Bułdak RJ, Zwirska-Korczala K. Potential role of leptin, adiponectin and three novel adipokines-visfatin, chemerin and vaspin-in chronic hepatitis. Mol. Med. 2011, 17:1397–410. doi: 10.2119/molmed.2010.00105 21738955

9. Kukla M, Zwirska-Korczala K, Hartleb M, Waluga M, Chwist A, Kajor M, et al. Serum chemerin and vaspin in non-alcoholic fatty liver disease. Scand. J. Gastroenterol. 2010, 45: 235–242. doi: 10.3109/00365520903443852 20095887

10. Stastny J, Bienertova-Vasku J, Vasku A. Visfatin and its role in obesity development. Diabetes Metab. Syndr. 2012, 6: 120–4. doi: 10.1016/j.dsx.2012.08.011 23153983

11. Bi TQ, Che XM. Nampt/PBEF/visfatin and cancer. Cancer Biol. Ther. 2010, 10: 119–25. doi: 10.4161/cbt.10.2.12581 20647743

12. Raghu A, Bee KT, Anu P, Jing Ch, Harpal SR. Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signalling pathways: novel insights into visfatin-induced angiogenesis. Cardiovascular Research. 2008, 78: 356–365. doi: 10.1093/cvr/cvm111 18093986

13. Moschen AR, Kaser A, Enrich B, Mosheimer B, Theurl M, Niederegger H, et al, Visfatin an adipocytokine with proinflammatory and immunomodulating properties. J. Immunol. 2007, 178: 1748–58. doi: 10.4049/jimmunol.178.3.1748 17237424

14. Booth A, Magnuson A, Fouts J, Foster M. Adipose tissue, obesity and adipokines: role in cancer promotion. Horm. Mol. Biol. Clin. Investig. 2015, 21: 57–74. doi: 10.1515/hmbci-2014-0037 25781552

15. Ninomiya S, Shimizu M, Imai K. Possible role of visfatin in hepatoma progression and the effects of branched-chain amino acids on visfatin-induced proliferation in human hepatoma cells. Cancer Prev. Res. (Phila). 2011, 4: 2092–2100. doi: 10.1158/1940-6207.CAPR-11-0340 21952585

16. Akbal E, Koçak E, Taş A, Yüksel E, Köklü S. Visfatin levels in nonalcoholic fatty liver disease. J. Clin. Lab. Anal. 2012, 26: 115–9. doi: 10.1002/jcla.21491 22467327

17. Hida K, Wada J, Eguchi J, et al. Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. USA Proc. Natl. Acad. Sci. 2005, 102: 10610–5.

18. Klöting N, Berndt J, Kralisch S. et al. Vaspin gene expression in human adipose tissue: association with obesity and type 2 diabetes. Biochem. Biophys. Res. Commun. 2006, 339: 430–6. doi: 10.1016/j.bbrc.2005.11.039 16298335

19. Rabe K, Lehrke M, Parhofer KG. et al. Adipokines and insulin resistance. Mol. Med. 2008, 14: 741–751. doi: 10.2119/2008-00058.Rabe 19009016

20. Kukla M, Waluga M, Sawczyn T et al. Serum vaspin may be a good indicator of fibrosis in chronic hepatitis C and is not altered by antiviral therapy. Pol. J. Pathol. 2012, 63: 213–220. https://doi.org/10.5114/pjp.2012.32767.

21. WHO. Physical Status: The Use and Interpretation of Anthropometry: Report of a World Health Organization (WHO) Expert Committee. 1995, Geneva, World Health Organization.

22. World Health Organization. Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycemia: Report of a WHO/IDF Consultation. 2006, Geneva, World Health Organization.

23. Filippatos TD, Derdemezis CS, Kiortsis DN, Tselepis AD, Elisaf MS. Increased plasma levels of visfatin/pre-B cell colony-enhancing factor in obese and overweight patients with metabolic syndrome. J. Endocrinol. Invest. 2007, 30: 323–6. doi: 10.1007/bf03346300 17556870

24. Li Y, Zhang Y, Dorweiler B, Cui D, Wang T, Woo CW et al. Extracellular Nampt promotes macrophage survival via a nonenzymatic interleukin-6/STAT3 signaling mechanism. J. Biol. Chem. 2008, 283: 34833–43. doi: 10.1074/jbc.M805866200 18945671

25. Van Gool F, Galli M, Gueydan C, Kruys V, Prevot PP, Bedalov A, et al. Intracellular NAD levels regulate tumor necrosis factor protein synthesis in a sirtuin-dependent manner. Nat. Med. 2009, 15: 206–10. doi: 10.1038/nm.1906 19151729

26. Buldak RJ, Buldak L, Polaniak R, Kukla M, Birkner E, Kubina R, et al. Visfatin affects redox adaptative responses and proliferation in Me45 human malignant melanoma cells: an in vitro study. Oncol. Rep. 2013, 29: 771–8. doi: 10.3892/or.2012.2175 23232726

27. Adya R, Tan BK, Punn A, Chen J, Randeva HS. Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signalling pathways: novel insights into visfatin-induced angiogenesis. Cardiovasc. Res. 2008, 78: 356–365. doi: 10.1093/cvr/cvm111 18093986

28. Tsai IT, Wang CP, Yu TH, Lu YC, Lin CW, Lu LF et al. Circulating visfatin level is associated with hepatocellular carcinoma in chronic hepatitis B or C virus infection. Cytokine. 2017, 90: 54–59. doi: 10.1016/j.cyto.2016.10.007 27770715

29. Sun Y, Zhu S, Wu Z, Huang Y, Liu C, Tang S, et al. Elevated serum visfatin levels are associated with poor prognosis of hepatocellular carcinoma. Oncotarget. 2017, 8: 23427–23435. doi: 10.18632/oncotarget.15080 28178643

30. Fukuhara A, Matsuda M, Nishizawa M, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science. 2005, 307: 426–430. doi: 10.1126/science.1097243 15604363

31. Nourbakhsh M, Nourbakhsh M, Gholinejad Z, Razzaghy-Azar M. Visfatin in obese children and adolescents and its association with insulin resistance and metabolic syndrome. Scand. J. Clin. Lab. Invest. 2015, 75: 183–8. doi: 10.3109/00365513.2014.1003594 25723377

32. Brown JE, Onyango DJ, Ramanjaneya M, Conner AC, Patel ST, Dunmore SJ, et al. Visfatin regulates insulin secretion, insulin receptor signalling and mRNA expression of diabetes-related genes in mouse pancreatic β-cells. J. Mol. Endocrinol. 2010, 44: 171–178. doi: 10.1677/JME-09-0071 19906834

33. Kabir F, Jahan FA, Khan I, Faruque MO, Hassan Z, Ali L. Increased concentration of circulating visfatin associates with post‐challenged hyperglycaemia and insulin resistance in IGT subjects. J. Taibah. Univ. Med. Sci. 2015, 10: 481–487. https://doi.org/10.1016/j.jtumed.2014.12.007.

34. Jung CH, Lee WJ, Hwang JY, Lee MJ, Seol SMs et al. Vaspin Increases Nitric Oxide Bioavailability through the Reduction of Asymmetric Dimethylarginine in Vascular Endothelial Cells. PLoS ONE. 2012, 7, e52346. doi: 10.1371/journal.pone.0052346 23284999

35. Kukla M, Waluga M, Żorniak M, Berdowska A, Wosiewicz P, Sawczyn T, et al. Serum omentin and vaspin levels in cirrhotic patients with and without portal vein thrombosis. World. J. Gastroenterol. 2017, 23: 2613–2624. doi: 10.3748/wjg.v23.i14.2613 28465646

36. Fazeli MS, Dashti H, Akbarzadeh S, Assadi M, Aminian A, Keramati MR, et al. Circulating levels of novel adipocytokines in patients with colorectal cancer. Cytokine. 2013, 62: 81–5. doi: 10.1016/j.cyto.2013.02.012 23474107

37. Cymbaluk-Płoska A, Chudecka-Głaz A, Jagodzińska A, Pius-Sadowska E, Sompolska-Rzechuła A, Machaliński B, et al. Evaluation of biologically active substances promoting the development of or protecting against endometrial cancer. Onco. Targets Ther. 2018, 11: 1363–1372. doi: 10.2147/OTT.S155942 29559794

38. Seeger J, Ziegelmeier M, Bachmann A, Lössner U, Kratzsch J, Blüher M. Serum levels of the adipokine vaspin in relation to metabolic and renal parameters. J. Clin. Endocrinol. Metab. 2008, 93:247–51. doi: 10.1210/jc.2007-1853 17956947

39. Rabe K, Lehrke M, Parhofer KG, Broedl UC. Adipokines and insulin resistance. Mol. Med. 2008, 14: 741–751. doi: 10.2119/2008-00058.Rabe 19009016

40. Kukla M, Piotrowski D, Waluga M, Hartleb M. Insulin resistance and its consequences in chronic hepatitis C. Clin. Exp. Hepatol. 2015, 1: 17–29. doi: 10.5114/ceh.2015.51375 28856251


Článek vyšel v časopise

PLOS One


2020 Číslo 1